1h Free Analyst Time
The rare hemophilia factors market is forecasted to grow by USD 208.6 million during 2023-2028, accelerating at a CAGR of 10.04% during the forecast period. The report on the rare hemophilia factors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by approval of new treatment techniques, introduction of cost-effective and high-quality medical solutions, and favorable government initiatives.
The rare hemophilia factors market is segmented as below:
By Method
- Fresh frozen plasma
- Factor concentrates
- Cryoprecipitate
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the rare hemophilia factors market covers the following areas:
- Rare hemophilia factors market sizing
- Rare hemophilia factors market forecast
- Rare hemophilia factors market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Method
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
360 degree market analysis
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global rare hemophilia factors market: Alnylam Pharmaceuticals Inc., Aptevo Therapeutics Inc., Bayer AG, Bio Products Laboratory Ltd., CSL Ltd., F. Hoffmann La Roche Ltd., Genentech Inc., Grifols SA, Gyre Therapeutics Inc., Intermountain Healthcare, Kedrion Spa, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., The Johns Hopkins Health System Corp., UCSF Health, uniQure NV, and Versiti.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advent of gene therapy."
According to the report, one of the major drivers for this market is the approval of new treatment techniques.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals Inc.
- Aptevo Therapeutics Inc.
- Bayer AG
- Bio Products Laboratory Ltd.
- CSL Ltd.
- F. Hoffmann La Roche Ltd.
- Genentech Inc.
- Grifols SA
- Gyre Therapeutics Inc.
- Intermountain Healthcare
- Kedrion Spa
- Novo Nordisk AS
- Octapharma AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- The Johns Hopkins Health System Corp.
- UCSF Health
- uniQure NV
- Versiti
